Aug 5 (Reuters) - Senti Biosciences Inc SNTI.O:
SENTI BIO DETERMINES RECOMMENDED PHASE 2 DOSE (RP2D) IN PHASE 1 STUDY OF SENTI-202 FOR THE TREATMENT OF RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES, INCLUDING ACUTE MYELOID LEUKEMIA
SENTI BIOSCIENCES INC - SENTI-202 WELL-TOLERATED, NO DOSE LIMITING TOXICITIES
SENTI BIOSCIENCES - EXPECTS TO REPORT CLINICAL DATA, INCLUDING EFFICACY & DURABILITY, FROM EXPANSION COHORT BEFORE YEAR-END